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Malaria affects almost all blood components and is 
a true haematological infectious disease. Anaemia and 
thrombocytopenia are the most frequent malaria-associ-
ated haematological complications (Wickramasinghe & 
Abdalla 2000) and have received more attention in the sci-
entific literature due to their associated mortality. On the 
other hand, thrombocytopenia is less studied, causes neg-
ligible mortality and is an isolated phenomenon; there is 
no report of a single patient in the literature who has died 
only because of malaria-associated thrombocytopenia.
In the current field of Travel Medicine, the rapid in-
crease in the number of people travelling to tropical areas 
has added a great challenge for malaria diagnosis because 
the thick blood smear (the standard diagnosis in endemic 
areas) has high specificity but only when performed by 
experienced microscopists. The presence of thrombocy-
topenia in acute febrile travellers returning from tropi-
cal areas has become a highly sensitive clinical marker 
for malaria diagnosis (D’Acremont et al. 2002). Another 
study has reported 60% sensitivity and 88% specificity 
of thrombocytopenia for malaria diagnosis in acute fe-
brile patients (Lathia & Joshi 2004). The sensitivity of 
thrombocytopenia together with the acute febrile syn-
drome was 100% for malaria diagnosis, with a specificity 
of 70%, a positive predictive value of 86% and a negative 
predictive value of 100% (Patel et al. 2004).
Thrombocytopenia is a well-documented and fre-
quent complication in Plasmodium vivax malaria. In 
one study, platelet count normalised after treatment and 
only one patient, concomitant with the lowest platelet 
count, exhibited “purpuric lesions” on the lower ex-
tremities (Hill et al. 1964).
Since the beginning of the 1970s, there have been 
reports proposing that malaria-associated thrombocy-
topenia is quite similar in P. vivax and Plasmodium fal-
ciparum infections (Beale et al. 1972). However, more 
recent data in India has shown how thrombocytopenia 
exhibited a heightened frequency and severity among 
patients with P. vivax infection (Kochar et al. 2010).
In 1903, the young physician Carlos Chagas (who 
become more famous afterwards for the discovery of 
American trypanosomiasis, which is named after him), 
published his MD thesis on the Hematological Stud-
ies on Paludism (Chagas 1903). Within it, he described 
anaemia and leukocyte abnormalities, but also normal 
megakaryocytes in the bone marrow were referred to in 
patients with acute and chronic malaria from Rio de Ja-
neiro. He also drew our attention to evidence of bleeding 
in the 46 patients he followed.
In the city of Manaus, state of Amazonas, located in 
the Western Brazilian Amazon, Djalma Batista authored 
Paludism in the Amazon, a book in which he described 
observations about patients with malaria seen at his pri-
vate clinics (Batista 1946). Similar to Carlos Chagas, 
there is no mention of platelet count in his study because 
it was not routinely performed. However, there is a vivid 
description of haemostasis disorders in some patients. 
Particularly noteworthy is the presence of huge spleen 
enlargement and prolonged bleeding time accompanied 
by recurrent gingival bleeding.
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Despite not being a criterion for severe malaria, thrombocytopenia is one of the most common complications 
of both Plasmodium vivax and Plasmodium falciparum malaria. In a systematic review of the literature, platelet 
counts under 150,000/mm3 ranged from 24-94% in patients with acute malaria and this frequency was not different 
between the two major species that affected humans. Minor bleeding is mentioned in case reports of patients with P. 
vivax infection and may be explained by medullary compensation with the release of mega platelets in the peripheral 
circulation by megakaryocytes, thus maintaining a good primary haemostasis. The speculated mechanisms leading 
to thrombocytopenia are: coagulation disturbances, splenomegaly, bone marrow alterations, antibody-mediated 
platelet destruction, oxidative stress and the role of platelets as cofactors in triggering severe malaria. Data from 
experimental models are presented and, despite not being rare, there is no clear recommendation on the adequate 
management of this haematological complication. In most cases, a conservative approach is adopted and platelet 
counts usually revert to normal ranges a few days after efficacious antimalarial treatment. More studies are needed 
to specifically clarify if thrombocytopenia is the cause or consequence of the clinical disease spectrum.
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Data on the real burden of thrombocytopenia associ-
ated with malaria is contradictory in the literature and 
it is not usually considered when conducting patient se-
lection. Table I shows the major publications estimating 
the frequency of thrombocytopenia. Most of these data 
were published in the late 1990s, probably in time with 
the surge in the availability of affordable automated ma-
chines capable of performing full blood counts (FBC). 
Manual platelet counting is time-consuming and usually 
needs to be requested by the physician with the routine 
blood count in most of the endemic areas for malaria. In 
only three publications is there an adequate randomised 
enrollment of patients with appropriate sample size cal-
culation to estimate the frequency of bleeding and its 
association with the respective platelet count (Lacerda 
2007, Silva 2009, Kochar et al. 2010). Only one study 
has ruled out other common causes of thrombocytopenia 
that are also endemic in the studied area (Lacerda 2007). 
There is a wide range of thrombocytopenia occurrence 
in these reports, which may be explained by distinct se-
lection criteria of the enrolled patients. There are also 
differences in the selection of outpatients or inpatients 
from tertiary care centres that tend to present with severe 
thrombocytopenia. Furthermore, clinical manifestations 
of thrombocytopenia are usually described as case re-
ports and most of these are due to P. vivax (Table II). 
In 2005, 138 of 684 (20.1%) malarial cases hospital-
ised in a tertiary care centre in Manaus had thrombocy-
topenia as the cause of admission, which corresponded 
to 6.8% of hospitalisations due to all causes in this refer-
ence institution (unpublished observations). Hospitalisa-
tion, however, does not add any benefit to the patient and 
because there is no evidence for any intervention, this 
simply increases public health costs in underdeveloped 
and under-resourced areas.
Pathogenesis of malarial thrombocytopenia - Co-
agulation disturbances - A study based on 31 American 
soldiers in Vietnam with chloroquine-resistant falci-
parum malaria noted the following changes in the acute 
phase of the disease using the same patients as their own 
controls during convalescence: decrease in the platelet 
count and prothrombim activation time, increase in the 
activated thromboplastin time, and reduction in factors 
V, VII and VIII with normal fibrinogen (Dennis et al. 
1967). This report suggested that thrombocytopenia was 
simply a consequence of the coagulation disorders pre-
sented by these patients, an idea that persisted for many 
decades in the literature. In another series of 21 patients 
with falciparum malaria, six had developed disseminated 
intravascular coagulation (DIC). The authors noted that 
the patients with more severe thrombocytopenia also 
had DIC and that there was correlation between platelet 
count and C3 protein levels. However, the reduction in 
C3 was proportional to that in parasitaemia, suggesting 
that thrombocytopenia was not independently associ-
ated with C3 (Srichaikul et al. 1975). In Manaus, 2004, a 
study with falciparum and vivax patients demonstrated a 
negative correlation between platelet counts, thrombin-
anti-thrombin complex and D-dimers, suggesting that 
the activation of coagulation could be partially respon-
sible for thrombocytopenia (Marques et al. 2005).
Splenomegaly - The spleen in malaria has played a 
crucial role in the immune response against the parasite, 
as well as controlling parasitaemia due to the phagocyto-
sis of parasitised red blood cells (RBCs) (Engwerda et al. 
2005). Some data suggested that platelets were seques-
tered in the spleen during the acute infection (Skudowitz 
et al. 1973). In the experimental model with Plasmodium 
chabaudi, thrombocytopenia was absent in splenec-
tomised mice, showing that the spleen was essential for 
thrombocytopenia (Watier et al. 1992). The term hyper-
splenism was proposed to describe the clinical picture of 
the enlarged spleen followed by the decrease in one or 
more peripheral blood lineages (usually reverted after 
splenectomy), probably due to sequestration or destruc-
tion of cells inside the spleen, in liver diseases, which 
lead to increased portal system pressure. However, it is 
recently believed that not only mechanical alterations take 
place, but also compromise of haematopoietic growth 
factors produced in the liver (Peck-Radosavljevic 2001). 
On the other hand, the isolated spleen enlargement does 
not explain per se the destruction of cells as formerly be-
lieved. This organ represents outstanding architectural 
organisation and controls, with great sophistication, the 
exposure of cells screened by it. In patients with malaria, 
the increase in the macrophage-colony stimulating factor 
is associated to thrombocytopenia, suggesting that mac-
rophages play a role in the destruction of these particles 
(Lee et al. 1997). In the comparison of spleens from pa-
tients with severe falciparum malaria vs. those of control 
and septic patients, it was shown that splenic dendritic 
cells are increased in malaria and there is a reduction in B 
lymphocytes and macrophages in the splenic cords (Ur-
ban et al. 2005). The mechanisms related to the formation 
of splenic hematomas are mostly associated with P. vivax 
infection and the interface with thrombocytopenia is 
noted to be imprecise (Lacerda et al. 2007). In vivax ma-
laria, the role of the spleen in the expression of vir genes 
is still unrecognised. P. vivax passing through the spleen 
would activate the transcription of polymorphic Vir pro-
teins to escape from macrophage destruction in this or-
gan. On the other hand, these same proteins would permit 
the binding of parasitised RBCs to barrier cells, creating 
an isolated microenvironment in the spleen that would be 
rich in reticulocytes (del Portillo et al. 2004). More recent 
studies with the murine model of Plasmodium yoelii evi-
denced that there was higher parasite accumulation, re-
duced motility, loss of directionality, increased residence 
time and altered magnetic resonance only in the spleens 
of mice infected with the non-lethal 17X strain (Martin-
Jaular et al. 2011). This same model has never been used 
to study the role of the spleen in thrombocytopenia, but 
opens new avenues for functional and structural studies 
of this lymphoid organ.
Bone marrow alterations - The finding of a P. vivax 
trophozoite inside a human platelet suggested that throm-
bocytopenia could be the result of invasion of these par-
ticles by the parasites themselves, similar to what was 
classically proposed for RBCs. As these same authors did 
not find parasites inside megakaryocytes, they proposed 
that the penetration took place in the peripheral circu-
lation (Fajardo & Tallent 1974). However, this observa-
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TABLE I
Systematic review of studies, estimating thrombocytopenia in malarial patients (1997-2011)
References Study site Type of patients Age range Species n
Thrombocytopenia
 % [criterion (mm3)]
Mohanty et al. (1997) India Inpatients and outpatients All ages P.v. 24 29 (< 150,000)
P.f. 76 39 (< 150,000)
Noronha (1998) Brazil Inpatients and outpatients < 14 y P.f. 54 51.8 (< 150,000)
Kortepeter and Brown (1998) USA Inpatients and outpatients > 18 y P.f./P.v. 79 74 (< 150,000)
Murthy et al. (2000) India Inpatients 10-80 y P.f. 158 40.5 (< 150,000)
Gonzalez et al. (2000) Colombia Inpatients All ages P.f. 113 33.6 (< 150,000)
P.v. 128 39 (< 150.000)
Alecrim (2000) Brazil Inpatients > 12 y P.v. 73 91.8 (< 150,000)
Outpatients 319 60.8 (< 150,000)
Silva et al. (2000) Brazil Inpatients All ages P.v. 429 46.6 (< 140,000)
Oh et al. (2001) South Korea Inpatients and outpatients > 17 y P.v. 101 85.1 (< 150,000)
Robinson et al. (2001) Australia Inpatients NA P.f./P.v./P.o. 246 71 (< 150,000)
Mourão et al. (2001) Brazil Inpatients < 12 y P.f. 255 73.7 (< 150,000)
Lacerda et al. (2001) Brazil Inpatients > 12 y P.f. 218 87.6 (< 150,000)
Ladhani et al. (2002) Kenya Inpatients Children P.f. 1,369 56.7 (< 150,000)
Park et al. (2002) Brazil Inpatients All ages P.v. 237 61.6 (NA)
Mohapatra et al. (2002) India Inpatients and outpatients 15-60 y P.v. 110 3.6 (< 100,000)
Bashawri et al. (2002) Saudi Arabia Inpatients and outpatients 2 m-74 y P.v./P.f. 727 55.6 (< 150,000)
Araújo Filho et al. (2003) Brazil Inpatients and outpatients 4-64 y P.v. 68 20.6 (< 50,000)
Echeverri et al. (2003) Colombia Outpatients All ages P.v. 104 8 (< 130,000)
Jadhav et al. (2004) India Inpatients and outpatients All ages P.v. 973 65 (50,000-150,000)
P.f. 590 50 (50,000-150,000)
Marques (2004) Brazil Inpatients and outpatients > 15 y P.f. 44 79 (< 150,000)
P.v. 106 94 (< 150,000)
Rodriguez-Morales et al. (2005) Venezuela NA NA P.v. 116 87.6 (< 150,000)
Rodriguez-Morales et al. (2006) Venezuela Inpatients < 12 y P.v. 78 58.9 (< 150,000)
Casals-Pascual et al. (2006) Kenya Inpatients and outpatients 6 m-10 y P.f. 120 34.4 (< 150,000)
Kumar and Shashirekha (2006) India Inpatients and outpatients All ages P.v. 27 88.8 (< 150,000)
Lacerda (2007) Brazil Outpatients > 18 y P.v. 142 71.8 (< 150,000)
P.f. 26 65.4 (< 150,000)
Koltas et al. (2007) Turkey Outpatients All ages P.v. 90 NA
Taylor et al. (2008) Indonesia Outpatients All ages P.v./P.f. 151 78.8 (< 150,000)
Tan et al. (2008) Thailand Inpatients and outpatients Pregnant 
women
P.v. 523 22 (< 75,000)
P.f. 694 34 (< 75,000)
Silva (2009) Brazil Outpatients All ages P.v. 397 77.1 (< 150,000)
Rasheed et al. (2009) Pakistan Inpatients All ages P.v./P.f 502 80 (< 150,000)
Shaikh et al. (2009) Pakistan Outpatients All ages P.v./P.f. 124 82.5 (< 150,000)
Prasad et al. (2009) India Inpatients < 5 y P.f. 40 85 (< 150,000)
Gonzalez et al. (2009) Venezuela Outpatients 3-67 P.v. 59 55.9 (< 150,000)
Poespoprodjo et al. (2009) Indonesia Inpatients 0-3 m P.v./P.f. and mixed 179 61.3 (< 100,000)
Khan et al. (2009) Qatar Outpatients All ages P.v. 81 63 (< 150,000)
Maina et al. (2010) Kenya Outpatients < 5 y P.f. 523 49 (< 150,000)
Kochar et al. (2010) India Inpatients and outpatients All ages P.v./P.f. and mixed 1,064 24.6 (< 150,000)
George and Alexander (2010) India Inpatients 18-66 y P.v. 30 93.3 (< 150,000)
Srivastava et al. (2011) India Inpatients All ages P.v. 50 82 (< 150,000)
m: months; NA: non-available; P.f.: Plasmodium falciparum; P.o.: Plasmodium ovale; P.v.: Plasmodium vivax; y: years. 
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tion was never seen again in the literature. Likewise, a 
“dysmegakaryopoiesis” was proposed, similar to what 
happened in the human malarial anaemia model, where 
dyserythropoiesis was triggered by cytokines (Menen-
dez et al. 2000). In the few studies that examined the 
bone marrow for this purpose, megakaryocytic lineage 
was apparently preserved (Naveira 1970, Beale et al. 
1972). Thrombopoietin indeed seems to rise during the 
acute disease even in the presence of liver compromise, 
suggesting that no bone marrow inhibition is seen (Kreil 
et al. 2000). Additional data from FBC samples in vivax 
patients showed that there is a significant negative cor-
relation between platelet count and mean platelet volume 
(Lacerda 2007), suggesting that megakaryocytes are able 
to release mega platelets in the circulation to compensate 
for the low absolute number of platelets in the periph-
ery. Similar results were shown in children with falci-
parum malaria (Maina et al. 2010). These mega platelets 
are probably able to sustain a good primary haemostasis 
that could explain the low frequency of severe bleeding 
in malarial patients, as shown in Table II. Non-human 
primates, on the other hand, are an unexplored model to 
study megakaryopoiesis alterations and its implication 
on thrombocytopenia (Llanos et al. 2006).
Antibody-mediated platelet destruction - There is ev-
idence that platelet-associated IgG (PAIgG) is increased 
in malaria and is associated with thrombocytopenia. 
However, this is a generic definition for all types of 
IgGs that may be found on the platelet surface, including 
antibodies stored inside platelet α-granules. Therefore, 
increased PAIgG could also be interpreted as platelet ac-
tivation and exposition of IgGs on the surface, and not 
necessarily auto-immunity, as suggested in anecdotal 
case reports where antibodies against glycoproteins 
were detected in malaria (Panasiuk 2001, Conte et al. 
2003). The detection of auto-antibodies against platelets 
by flow cytometry (Rios-Orrego et al. 2005) should not 
be seen as specific for malaria, as natural auto-antibody 
formation is a common defence of the infected organism 
TABLE II






Hill et al. (1964) United States of America 20-49 Petecchiae No Experimental infection
Takaki et al. (1991) Solomon Islands NA NA NA DIC
Anstey et al. (1992) Bali 22 No No -
Ohtaka et al. (1993) NA NA NA NA PAIgG increase
Yamaguchi et al. (1997) Thailand and Sri Lanka 22-53 No No PAIgG increase
Victoria et al. (1998) Brazil 1 Several Yes ITP
Kakar et al. (1999) India 5 No No -
Makkar et al. (2002) India 8 Gingival bleeding Yes -
Holland et al. (2004) Mexico 19 Epistaxis Yes -
Lacerda et al. (2004) Brazil 1 Gingival bleeding Yes ITP
Aggarwal et al. (2005) India 6 Petecchiae Yes -
Katira and Shah (2006) India 14-92 No Yes -
Komoda et al. (2006) South America 15 NA NA -
Kaur et al. (2007) India 30 No No Acute renal failure
Song et al. (2007) South Korea 25-20 No No DIC, lung edema, acute 
renal failure and shock
Kaur et al. (2007) India 30 Petecchiae No Acute renal failure
Lacerda et al. (2008) Brazil 6 No No Chronic splenomegaly
Vij et al. (2008) India NA Gingival bleeding No NA
Rifakis et al. (2008) Venezuela 57 No No Hydronephrosis and shock
Parakh et al. (2009) India 5-42 Petecchiae No Cerebral malaria, shock 
and acute renal failure
Thapa et al. (2009) India 11 Petecchiae and 
mucosal bleeding
Yes Hepatitis and shock
Harish and Gupta (2009) India 1 Intracranial bleed No Seizures
Bhatia and Bhatia (2010) India NA Yes NA NA
DIC: disseminated intravascular coagulation; ITP: immune thrombocytopenic purpura; NA: non-available; PAIgG: platelet-
associated IgG.
56 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(Suppl. I), 2011
and is frequently seen in most viral, bacterial and para-
sitic diseases without any repercussion (Daniel-Ribeiro 
& Zanini 2000). Molecular mimicry, however, provides 
evolutionary advantage for microorganisms that escape 
immune aggression (Daniel-Ribeiro 2000). The rela-
tionship between malaria and auto-immunity has been 
discussed in the literature and the first epidemiological 
association was made based on the presence of fewer au-
to-immune diseases in malarigenous areas (Greenwood 
1968). The formation of circulating immune complexes 
(CIC) in vivo in malaria, as well as in other infectious 
diseases, is a continuous process from antigens and 
antibodies and/or complement elements. CIC seems to 
modulate the immune response to several antigens that 
remain sequestered in B lymphocyte or dendritic cell-
rich follicles for a longer time, which contributes to the 
formation of B-cell immunological memory, as seen in 
vaccine studies (Davidson 1985). During acute malaria, 
thrombocytopenia is most probably associated with the 
binding of parasite antigens to the surface of platelets to 
which antimalarial antibodies also bind, leading to the 
in situ formation of immune complexes (ICs) (Kelton et 
al. 1983). In an experimental model with Plasmodium 
berghei, the same correlation between platelet count and 
IC’s was evidenced (Grau et al. 1988). No association 
was found with IgM (Beale et al. 1972). It is clear that 
CICs are elevated in vivax and falciparum malaria, but 
their role in the development of thrombocytopenia is still 
obscure (Touze et al. 1990, Tyagi & Biswas 1999) as well 
as its immune suppressing effect (Brown & Kreier 1982, 
Shear 1984). Because the generation of IC’s is propor-
tional to the amount of available antigen, the negative 
correlation between platelet count and peripheral para-
sitaemia reported in many studies (Lacerda 2007, Sil-
va 2009) corroborates ICs as a potential mechanism of 
platelet destruction. The presence of amino acid residues 
tyrosine 193 [9Y(193)] and serine 210 [S(210)] on apical 
membrane antigen-1 (AMA-1) was significantly associ-
ated with normal platelet counts in P. vivax malaria in-
dependent of the level of parasitaemia that also provides 
supporting evidence for this (Grynberg et al. 2007). In 
only one study, circulating monocytes were found to 
phagocytose platelets, but this mechanism still needs to 
be associated to thrombocytopenia more closely (Jaff 
et al. 1985). The finding of immune thrombocytopenic 
purpura (ITP) secondary to malarial infection is rare and 
may be due to idiosyncratic auto-immune mechanisms 
not well understood (Lacerda et al. 2004).
Oxidative stress - Free radicals may play an impor-
tant role in the platelet destruction in malarial infection. 
There is evidence that the decrease in total cholesterol in 
vivax malaria is due to lipidic peroxidation (Erel et al. 
1998). Also, in vivax malaria, there is a negative correla-
tion between platelet count and platelet lipid peroxida-
tion in addition to the positive correlation between plate-
let count and the activity of gluthatione peroxidase and 
superoxide dismutase, which are considered anti-oxidant 
enzymes (Erel et al. 2001). In a study of 103 patients with 
acute falciparum malaria, there was a negative correla-
tion between platelet count and nitrogen reactive inter-
mediates (Santos 2000). There is also a strong associa-
tion between platelet count and intra-platelet gluthatione 
peroxidase, suggesting that a compensatory mechanism 
is presented by platelets to face the oxidative burst found 
in malaria (Araujo et al. 2008).
Platelet aggregation - Platelets from patients with 
acute malaria are highly sensitive to adenosine diphos-
phate (ADP) addition in vitro (Essien & Ebhota 1981), 
and it is believed that ADP release following haemolysis 
could contribute to higher platelet aggregation. Actually, 
the incubation of platelets with P. falciparum-parasitised 
RBCs also increases platelet aggregation per se in vitro, 
especially after ADP and thromboxane A2 addition (In-
yang et al. 1987). Even electron microscopic examination 
of non-stimulated, fresh platelets from malarial patients 
show centralisation of dense granules, glycogen deple-
tion and microaggregates and phylopoids as a sign of in 
vivo activation, which could be responsible for a pseudo-
thrombocytopenia due to sequestration of these activated 
particles in the interior of the vessels (Mohanty et al. 
1988). Contradictory data were presented showing ag-
gregation impairment in severe falciparum patients after 
ADP addition in vitro (Srichaikul et al. 1988). P. falci-
parum induces systemic acute endothelial cell activation 
and the release of activated von Willerbrand factor (vWF) 
immediately after the onset of the blood-stage infection 
(Mast et al. 2007). Even without consumptive coagulopa-
thy, the increase in soluble glycoprotein-1b (GP1b) con-
centrations results from vWF-mediated GP1b shedding, 
a process that may prevent excessive adhesion of platelets 
and parasitised erythrocytes (Mast et al. 2010). Antima-
larial drugs have also been shown as potential inhibitors 
of platelet aggregation in vivo and in vitro, what precludes 
careful inclusion and exclusion criteria of patients to be 
used in clinical research (Cummins et al. 1990).
The relationship between thrombocytopenia and se-
vere malaria - Severe thrombocytopenia (platelet count 
under 50,000/mm3), despite not being considered severe 
malaria according to World Health Organization criteria 
(WHO 2010) due to the inability to cause death per se, 
has been occasionally associated with severity (Gerardin 
et al. 2002, Rogier et al. 2004) or not (Moulin et al. 2003). 
But thrombocytopenia has also been described in severe 
vivax patients (Kochar et al. 2005, Andrade et al. 2010). 
In 17 patients from Manaus affected by any of the WHO 
malaria severity criteria with confirmed P. vivax monoin-
fection, 14 presented with thrombocytopenia, suggesting 
that this haematological complication can be explored 
as a marker of the severity for this species (Alexandre 
et al. 2010). From the case reports described in Table 
II, the association between severe cases with thrombo-
cytopenia is evident. However, that can be due to bias 
publication, where prospective studies would be needed 
to validate this association. On the other hand, consider-
ing that many studies point to a clear negative correlation 
between platelet count and parasitaemia (Grynberg et 
al. 2007, Silva 2009), it should be investigated if throm-
bocytopenia could be used in the surveillance of drug 
resistance, where higher parasitaemias for prolonged 
periods are usually found. Interestingly, in areas where 
thrombocytopenia and other types of clinical severity are 
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frequently reported, resistant parasites are also being si-
multaneously detected (Santana Filho et al. 2007, Tjitra 
et al. 2008), possibly explaining why the prevalence of 
thrombocytopenia worldwide is not homogeneous.
On the other side of the clinical presentation of plasmo-
dial infection, platelet counts were never performed in as-
ymptomatic parasite carriers. However, due to the very low 
parasitaemia (sometimes submicroscopic) presented by 
these patients, it is possible that platelet counts are normal 
and parallel clinical symptoms (Suarez-Mutis et al. 2007).
Avoiding the consensual understanding that platelets 
are particles devoted to the maintenance of primary hae-
mostasis, it has been shown that platelets participate in the 
pathogenesis of microvascular malaria, adhering to the 
endothelium when it is previously stimulated with tumor 
necrosis factor (TNF) (Lou et al. 1997). Even in the non-
stimulated cerebral endothelium, platelets may adhere 
and facilitate the adhesion of P. falciparum-parasitised 
RBCs, through CD36 is ubiquitous in endothelial cells 
and, coincidentally, platelets (Wassmer et al. 2004). Plate-
lets therefore act by stabilising and strengthening bridges 
between RBCs and endothelial cells, which is considered 
the cornerstone of severe falciparum malaria. Rosetting 
of parasitised RBCs is also mediated through CD36 in 
platelets in severe malaria (Pain et al. 2001, Chotivanich et 
al. 2004). In mice infected with P. berghei ANKA, mice 
deficient of tissue and uroquinase plasminogen activators 
demonstrated less capillary sequestration of platelets and 
less severe malaria (Piguet et al. 2000). Blocking GPIIb 
with anti-CD41 monoclonal antibodies in the first day of 
murine infection with P. berghei also led to higher pro-
duction of interleukin (IL)-10, IL-1α, IL-6, interferon-α 
and TNF and less mortality among mice, suggesting that 
platelets may act as cofactors of severe malaria (Sun et 
al. 2003, van der Heyde et al. 2005). There was also an 
inverse correlation between platelet count and TNF in 
patients with vivax infection and no association between 
specific mutation G→A in the position 308 in the TNF 
gene (a polymorphism whose functional effect upon 
severe disease is hypothesised) and platelet count was 
observed. More severe patients presented more severe 
thrombocytopenia and higher TNF levels (Silva 2004). 
Platelets stimulated by parasitised RBCs may also trigger 
apoptosis in endothelial cells pre-treated with TNF in a 
pathway mediated by tumor growth factor (TGF)-β1 from 
platelets (Wassmer et al. 2006a, b). Recent evidence show-
ing P. vivax-infected RBCs adhering to lung endothelial 
cells and to the placental tissue ex vivo indicates that in 
vivax, mechanisms similar to those associated with fal-
ciparum severity may be involved (Carvalho et al. 2010). 
The contribution of platelets to this adhesion, however, 
requires further investigation.
In children in Kenya suffering from falciparum ma-
laria, an inverse correlation between platelet count and 
plasmatic IL-10 was seen (Casals-Pascual et al. 2006). 
This interpretation is not straightforward, because IL-
10 is generally associated with protection against severe 
disease. The authors hypothesise, though, that IL-10 
could reduce platelet counts to avoid infected-RBC ad-
hesion to the endothelium, as if thrombocytopenia was 
a mechanism of defence against severe disease and not 
the cause. Studies of vivax infection have shown throm-
bocytopenia to be associated with an increase in IL-1, 
IL-6, IL-10 and TGF-β (Park et al. 2003). 
The role of platelet-derived microparticles (MPs) 
(submicron-sized vesicles released from cells upon ac-
tivation or apoptosis) has yet to be determined in vivo. 
There is evidence that these MPs participate in the en-
dothelial activation responsible for severe cerebral ma-
laria in murine models (Combes et al. 2006). MPs were 
also associated with coma and thrombocytopenia in se-
vere falciparum malaria patients (Pankoui Mfonkeu et al. 
2010). Apparently, there is an increase in the amount of 
MPs in vivax malaria patients, which may play a role in 
the acute inflammatory symptoms of this disease (Cam-
pos et al. 2010); this role requires further investigation.
Clinical management of malarial thrombocytopenia 
- To date, there is no robust evidence on how to manage 
patients with malaria and thrombocytopenia. Platelet 
transfusion has been widely followed, but with no con-
firmed efficacy. The indication of prophylactic platelet 
transfusion when platelet counts are under 10,000/mm3 
probably applies only when the bone marrow is compro-
mised and is not able to release efficacious platelets (Re-
bulla 2000). This does not seem to be the case in malar-
ia. Keeping platelet counts between 50,000 and 100,000/
mm3 is a formal indication only in patients undergoing 
surgical procedures (Rebulla 2001). In a tertiary care 
centre in the Western Brazilian Amazon over a 12-month 
period, 10.4% (20/191) of patients who received platelet 
transfusion were diagnosed with vivax or falciparum 
malaria (Lacerda et al. 2006). The dosage was usually 
below that recommended in the literature (Schlossberg & 
Herman 2003). In 40% of patients, the only justifications 
for transfusion were maintaining a platelet count below 
10,000/mm3 and discrete bleeding. In a further 6% of 
patients, only a very low platelet count was described. In 
this group of 40% of patients, the alleged reason was mi-
nor bleeding despite having non-severe thrombocytope-
nia; in 33%, no indication was verified. These data point 
to the little existing evidence of the recommendations 
for platelet transfusion in these patients. The corrected 
count increment to evaluate transfusion efficacy was not 
calculated for any patient. The low efficacy of platelet 
transfusion in general is well described for several acute 
infectious diseases (de Paula et al. 1993), probably due to 
peripheral immune mechanisms of destruction that do 
not spare the transfused platelets. Indications for platelet 
transfusion in cases when DIC is suspected and diag-
nosed, the formal clinical indication persists, as recom-
mended elsewhere (Franchini 2005). Due to the impossi-
bility of using frozen platelets in routine clinical practice, 
other platelet substitutes and preparations are being in-
vestigated (Blajchman 2003). Except in atypical cases of 
ITP with severe bleeding, there is no evidence for the use 
of human intravenous immunoglobulin, even in cases of 
severe thrombocytopenia (Lacerda et al. 2004).
The use of corticoids has never been followed, prob-
ably due to the fact that the recovery of thrombocytope-
nia following antimalarial treatment is seen in almost 
all cases, with good prognosis for all species that infect 
humans (Lacerda 2007) and with the lack of robust evi-
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dence of immune-mediated destruction of platelets as a 
major mechanism. It was also found that in patients with 
cerebral falciparum malaria, dexamethasone exacer-
bated the neurological symptoms and increased the fre-
quency of gastrointestinal bleeding (Warrell et al. 1982, 
Hoffman et al. 1988). However, in none of these studies 
was platelet recovery analysed as a secondary endpoint. 
Immune modulators are also candidates in the adju-
vant antimalarial therapy (Muniz-Junqueira et al. 2005, 
Mohanty et al. 2006), based on the drug-induced inhibi-
tion of adhesion molecules in RBCs and platelets (Mu-
niz-Junqueira 2007). The exploration of drugs known by 
their anti-inflammatory effect, modulating TNF, e.g., 
pentoxyfylline and thalidomide, upon severe malaria, 
could not only contribute to the understanding of the 
mechanisms of severity but also clarify the association 
between platelets and severe disease.
Thrombocytopenia in other infectious diseases - 
Many other acute and chronic infectious diseases share 
similar thrombocytopenia as part of the clinical picture 
and these mechanisms may be used by proxy to explain 
malarial disease.
Chronic thrombocytopenia is found in approximately 
10% of patients with human immunodeficiency virus 
(HIV)-1 infection and in one-third of those with ac-
quired immunodeficiency syndrome (Scaradavou 2002). 
The first cases of homosexuals with profound thrombo-
cytopenia in New York were classified as ITP (Karpatkin 
2002), involving the presence of serum IgG anti-GPIIIa 
(Karpatkin et al. 1995). Later on, this IgG was found to 
be directed against GPIIIa49-66 (Nardi et al. 1997). More 
recently, molecular mimicry was proposed between nef 
HIV-1 protein and GPIIIa49-66 (Li et al. 2005). Other chron-
ic infectious diseases known to cause thrombocytopenia 
include chronic viral hepatitis, where CIC (Samuel et al. 
1999) and PAIgG (Doi et al. 2002) are also implicated. 
In the case of hepatitis C virus infection, the blockage 
in the maturation of megakaryocytes is mediated by the 
viral RNA itself (Almeida 2003). Despite an associated 
medullary compromise in visceral leishmaniasis in the 
canine model of Leishmania infantum infection, anti-
platelet IgG and IgM were also observed (Terrazzano 
et al. 2006). In acute infection with Trypanosoma cruzi, 
frequent thrombocytopenia is related to the presence of 
parasite trans-sialidase (Tribulatti et al. 2005). Further-
more, during infection with any of the four dengue vi-
ruses, thrombocytopenia is frequent and is supposed to 
be a criterion of dengue hemorrhagic fever (Mourão et 
al. 2007). Platelet phagocytosis ex vivo has already been 
shown as a potential mechanism in this acute viral dis-
ease (Honda et al. 2009). Thrombocytopenia is also ob-
served in leptospirosis (Nicodemo 1993), typhoid fever 
(Huang & DuPont 2005), hantavirus infection (Santos et 
al. 2006), yellow fever (Monath 2001) and sepsis (Becchi 
et al. 2006), whose mechanisms are poorly understood. 
The high frequency of thrombocytopenia in other infec-
tious diseases, as a rule, changes the paradigm that plate-
lets are essential only to haemostasis, supporting their 
role as important contributors to modulate the immune 
response. In any case, studies focusing on the pathogen-
esis of thrombocytopenia in malarial patients should 
always rule out other concomitant infectious diseases, 
which is difficult in socio-economically deprived study 
populations suffering large burdens of multiple diseases.
The frequency of thrombocytopenia (i.e., platelet 
count below 150,000/mm3) in malarial infection ranges 
from 24-94% in the literature, despite the low occurrence 
of severe bleeding, even in the case of severe malaria. It 
is still unclear whether this haematological complication 
is more frequent in P. vivax or P. falciparum malaria. In 
Figure, the major mechanisms involved in the pathogen-
esis are highlighted, but further studies are still needed to 
clarify the impact of each mechanism and its clinical rel-
evance. The clinical management of malarial thrombocy-
topenia is expectant and the level of evidence for platelet 
transfusion is insufficient to recommend this practice. It 
is not clear whether platelets are diminished during acute 
malarial infection as a consequence of the immune re-
sponse to the parasite present or whether platelets are ac-
tually involved in the generation of severe disease.
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